Combined use of liquid chromatography with mass spectrometry and nuclear magnetic resonance for the identification of degradation compounds in an erythromycin formulation

M. Pendela, S. Béni, E. Haghedooren, L. Van Den Bossche, B. Noszál, A. Van Schepdael, J. Hoogmartens, E. Adams

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

A commercial erythromycin formulation containing erythromycin A (EA) as the major compound showed the presence of an unknown degradation compound that was co-eluted with erythromycin E (EE) in the European Pharmacopoeia (Ph. Eur.) liquid chromatographic (LC) method. The amount of the degradation compound increased with respect to time. To separate this unknown (UNK1), investigation was performed with different LC methods coupled to ultraviolet detection (LC-UV). With the present Ph. Eur. method, the degradation compound could not be well separated. However, with the most selective LC-UV method (XTerra method), two more degradation products (UNK2 and UNK3) were found in the formulation which could not be observed using other methods because of their poor separation. By combining the results obtained with LC-UV, LC/MS and LC/NMR, the degradation products were identified as pseudoerythromycin A hemiketal (PsEAHK), erythromycin A enol ether carboxylic acid and erythromycin C enol ether carboxylic acid. PsEAHK is known to be a base-catalysed degradation product of EA, whereas the other two degradation products were newly identified.

Original languageEnglish
Pages (from-to)781-790
Number of pages10
JournalAnalytical and Bioanalytical Chemistry
Volume402
Issue number2
DOIs
Publication statusPublished - Jan 2012

Fingerprint

Liquid chromatography
Erythromycin
Liquid Chromatography
Mass spectrometry
Mass Spectrometry
Magnetic Resonance Spectroscopy
Nuclear magnetic resonance
Degradation
Liquids
Carboxylic Acids
Ether
Pharmacopoeias

Keywords

  • Degradation
  • Erythromycin
  • LC-UV
  • LC/MS
  • LC/NMR

ASJC Scopus subject areas

  • Analytical Chemistry
  • Biochemistry

Cite this

Combined use of liquid chromatography with mass spectrometry and nuclear magnetic resonance for the identification of degradation compounds in an erythromycin formulation. / Pendela, M.; Béni, S.; Haghedooren, E.; Van Den Bossche, L.; Noszál, B.; Van Schepdael, A.; Hoogmartens, J.; Adams, E.

In: Analytical and Bioanalytical Chemistry, Vol. 402, No. 2, 01.2012, p. 781-790.

Research output: Contribution to journalArticle

@article{77b6469c957249ddaa25e6ce07aa1e1c,
title = "Combined use of liquid chromatography with mass spectrometry and nuclear magnetic resonance for the identification of degradation compounds in an erythromycin formulation",
abstract = "A commercial erythromycin formulation containing erythromycin A (EA) as the major compound showed the presence of an unknown degradation compound that was co-eluted with erythromycin E (EE) in the European Pharmacopoeia (Ph. Eur.) liquid chromatographic (LC) method. The amount of the degradation compound increased with respect to time. To separate this unknown (UNK1), investigation was performed with different LC methods coupled to ultraviolet detection (LC-UV). With the present Ph. Eur. method, the degradation compound could not be well separated. However, with the most selective LC-UV method (XTerra method), two more degradation products (UNK2 and UNK3) were found in the formulation which could not be observed using other methods because of their poor separation. By combining the results obtained with LC-UV, LC/MS and LC/NMR, the degradation products were identified as pseudoerythromycin A hemiketal (PsEAHK), erythromycin A enol ether carboxylic acid and erythromycin C enol ether carboxylic acid. PsEAHK is known to be a base-catalysed degradation product of EA, whereas the other two degradation products were newly identified.",
keywords = "Degradation, Erythromycin, LC-UV, LC/MS, LC/NMR",
author = "M. Pendela and S. B{\'e}ni and E. Haghedooren and {Van Den Bossche}, L. and B. Nosz{\'a}l and {Van Schepdael}, A. and J. Hoogmartens and E. Adams",
year = "2012",
month = "1",
doi = "10.1007/s00216-011-5450-0",
language = "English",
volume = "402",
pages = "781--790",
journal = "Fresenius Zeitschrift fur Analytische Chemie",
issn = "1618-2642",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Combined use of liquid chromatography with mass spectrometry and nuclear magnetic resonance for the identification of degradation compounds in an erythromycin formulation

AU - Pendela, M.

AU - Béni, S.

AU - Haghedooren, E.

AU - Van Den Bossche, L.

AU - Noszál, B.

AU - Van Schepdael, A.

AU - Hoogmartens, J.

AU - Adams, E.

PY - 2012/1

Y1 - 2012/1

N2 - A commercial erythromycin formulation containing erythromycin A (EA) as the major compound showed the presence of an unknown degradation compound that was co-eluted with erythromycin E (EE) in the European Pharmacopoeia (Ph. Eur.) liquid chromatographic (LC) method. The amount of the degradation compound increased with respect to time. To separate this unknown (UNK1), investigation was performed with different LC methods coupled to ultraviolet detection (LC-UV). With the present Ph. Eur. method, the degradation compound could not be well separated. However, with the most selective LC-UV method (XTerra method), two more degradation products (UNK2 and UNK3) were found in the formulation which could not be observed using other methods because of their poor separation. By combining the results obtained with LC-UV, LC/MS and LC/NMR, the degradation products were identified as pseudoerythromycin A hemiketal (PsEAHK), erythromycin A enol ether carboxylic acid and erythromycin C enol ether carboxylic acid. PsEAHK is known to be a base-catalysed degradation product of EA, whereas the other two degradation products were newly identified.

AB - A commercial erythromycin formulation containing erythromycin A (EA) as the major compound showed the presence of an unknown degradation compound that was co-eluted with erythromycin E (EE) in the European Pharmacopoeia (Ph. Eur.) liquid chromatographic (LC) method. The amount of the degradation compound increased with respect to time. To separate this unknown (UNK1), investigation was performed with different LC methods coupled to ultraviolet detection (LC-UV). With the present Ph. Eur. method, the degradation compound could not be well separated. However, with the most selective LC-UV method (XTerra method), two more degradation products (UNK2 and UNK3) were found in the formulation which could not be observed using other methods because of their poor separation. By combining the results obtained with LC-UV, LC/MS and LC/NMR, the degradation products were identified as pseudoerythromycin A hemiketal (PsEAHK), erythromycin A enol ether carboxylic acid and erythromycin C enol ether carboxylic acid. PsEAHK is known to be a base-catalysed degradation product of EA, whereas the other two degradation products were newly identified.

KW - Degradation

KW - Erythromycin

KW - LC-UV

KW - LC/MS

KW - LC/NMR

UR - http://www.scopus.com/inward/record.url?scp=84856234564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856234564&partnerID=8YFLogxK

U2 - 10.1007/s00216-011-5450-0

DO - 10.1007/s00216-011-5450-0

M3 - Article

C2 - 22002558

AN - SCOPUS:84856234564

VL - 402

SP - 781

EP - 790

JO - Fresenius Zeitschrift fur Analytische Chemie

JF - Fresenius Zeitschrift fur Analytische Chemie

SN - 1618-2642

IS - 2

ER -